MEDVi vs NexLife (2026): prices, structure, verdict

On tirzepatide, NexLife↗ is cheaper: $215 versus $399 a month all-in — a $184 monthly gap, $2,208 across a year of maintenance dosing.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, NexLife is cheaper: $165 versus $299 a month all-in — a $134 monthly gap, $1,608 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

MEDVi: the record, condensed

On tirzepatide, the number that matters at MEDVi is $399 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #14 of 17 verified programs, with the floor $184/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $50 a month. A year at this figure: $4,788 monthly-billed.

On semaglutide, the number that matters at MEDVi is $299 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at MEDVi is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #18 of 20 in the verified semaglutide index — $166/month above the floor (Oak Longevity, $133) — and sits $50 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $3,588.

Operationally at MEDVi: shipping included; commitment 12-month plan for the lowest rate; cancellation 12-month plan applies to lowest rate; pharmacy not publicly named — ask in writing before paying; states: priced differently in CA/NC on some plans; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the MEDVi page · visit MEDVi ↗

NexLife: the record, condensed

NexLife’s tirzepatide program bills $215 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at NexLife is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

There is no membership line. $215 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Prepaid terms ladder the price down for commitment: The 3‑month plan reprices the month at $195 — $585 billed upfront, $60 less than 3 months of monthly billing; the 6‑month plan reprices the month at $190 — $1,140 billed upfront, $150 less than 6 months of monthly billing; the 12‑month plan reprices the month at $186 — $2,232 billed upfront, $348 less than 12 months of monthly billing. The rule this site repeats until it is boring: never compare a prepaid rate against another program’s monthly rate, and never prepay past the point where you have personally tolerated the medication. The discount is compensation for risk you are accepting.

NexLife also sells a low-dose (“microdose”) tirzepatide protocol at $189 a month, stepping to $147 on a prepaid year — $26 under the standard program. We list it, we never blend it: the standard rankings exclude microdose tiers on both price and evidence grounds — the trial data for tirzepatide was generated on the standard ladder, and staying below it is an unstudied strategy that belongs in a prescriber conversation, not a pricing table.

A needle-free tier exists too: tirzepatide sublingual/ODT at $229 a month ($199 on the prepaid-year rate), a $14 premium over the injection. Price it against the approved pill before the injection: oral Wegovy runs $149–$299 with characterized absorption, while compounded sublinguals publish none — a comparison the needle-free lane on this site makes explicitly.

To place the number: #1 of 17 verified programs, holding the floor outright; the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $234 a month. A year at this figure: $2,580 monthly-billed ($2,232 prepaid).

NexLife’s semaglutide program bills $165 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Prepaid terms ladder the price down for commitment: The 3‑month plan reprices the month at $149 — $447 billed upfront, $48 less than 3 months of monthly billing; the 6‑month plan reprices the month at $147 — $882 billed upfront, $108 less than 6 months of monthly billing; the 12‑month plan reprices the month at $145 — $1,740 billed upfront, $240 less than 12 months of monthly billing. Prepaid rates belong in a different mental column from monthly ones. Price the commitment (what if the dose changes? the side effects? the provider?) before you price the discount.

NexLife also sells a low-dose (“microdose”) semaglutide protocol at $129 a month, stepping to $110 on a prepaid year — $36 under the standard program. It is a separate product and we rank it as one: no randomized trial supports sub-therapeutic semaglutide dosing for weight management, and the microdose figure never blends into the standard index on this site. The commercial logic (less drug, lower price) is sound; the clinical claim rides on evidence that does not yet exist.

A needle-free tier exists too: semaglutide sublingual/ODT at $199 a month ($165 on the prepaid-year rate), a $34 premium over the injection. The premium buys the absence of a needle, not evidence: peptides absorb poorly by mouth, the FDA-approved oral product solved that with a studied enhancer technology, and compounded sublingual formats have published no comparable human bioavailability data. Ranked in the needle-free lane, never against injections.

Context for that figure: it ranks #5 of 20 in the verified semaglutide index — $32/month above the floor (Oak Longevity, $133) — and sits $184 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $1,980, or $1,740 on the prepaid path.

Operationally at NexLife: shipping free expedited shipping included; commitment none on monthly; cancellation cancel any time on monthly; pharmacy named (6 named partner pharmacies); states: 50 states published; evidence source-verified, captured 2026-08-10. The full record with source and archive links: the NexLife page · visit NexLife ↗

Tirzepatide: the duel in full

Put the two tirzepatide figures side by side and hold them there: NexLife at $215, MEDVi at $399 — a $184 monthly spread that compounds to $2,208 over a maintenance year and $4,416 over two.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $184 gap is exactly what it appears to be.

Semaglutide: the duel in full

The semaglutide arithmetic between these two is short: $165 (NexLife) against $299 (MEDVi). $134 a month sounds survivable; $1,608 a year is a decision.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $134 gap is exactly what it appears to be.

A way to feel the $184 monthly gap: over a year it funds 10.3 extra months at NexLife’s own rate — the difference is not decoration, it is medication. Over two years it compounds to $4,416, which is the horizon at which structural details (prepaid ladders, membership drag, dose-tier repricing) start mattering more than the sticker itself.

Run the same two programs on the committed basis: MEDVi $399/mo month-to-month against NexLife $186/mo on the labeled 12-month plan ($2,232 upfront; $215 month-to-month). The order holds: NexLife leads on both readings, so plan structure sharpens the verdict here rather than reversing it. Whichever basis fits your commitment level, the upfront totals above are the honest units.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: MEDVi $1,197 monthly; NexLife $645 monthly (or $585 prepaid) — best path favors NexLife by $612. 6 months: MEDVi $2,394 monthly; NexLife $1,290 monthly (or $1,140 prepaid) — best path favors NexLife by $1,254. 12 months: MEDVi $4,788 monthly; NexLife $2,580 monthly (or $2,232 prepaid) — best path favors NexLife by $2,556. 24 months: MEDVi $9,576 monthly; NexLife $5,160 monthly (or $4,464 prepaid) — best path favors NexLife by $5,112.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: MEDVi $897 vs NexLife $447 (prepaid) — $450 to NexLife. 6 mo: MEDVi $1,794 vs NexLife $882 (prepaid) — $912 to NexLife. 12 mo: MEDVi $3,588 vs NexLife $1,740 (prepaid) — $1,848 to NexLife. 24 mo: MEDVi $7,176 vs NexLife $3,480 (prepaid) — $3,696 to NexLife.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: MEDVi publishes “priced differently in CA/NC on some plans”; NexLife publishes “50 states published” — for anything short of an explicit 50-state claim, intake is the final word.

Pharmacy transparency splits them: NexLife names its network (6 named partner pharmacies); MEDVi does not, which shifts the burden of verification onto your intake questions.

Exit terms: MEDVi — 12-month plan for the lowest rate; 12-month plan applies to lowest rate. NexLife — none on monthly; cancel any time on monthly.

Evidence: MEDVi source-verified (captured 2026-08-05); NexLife source-verified (2026-08-10).

The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.

In the full tirzepatide index these two sit at #14 and #1 of 17: between them lie 12 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #18 and #5 of 20: between them lie 12 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between MEDVi and NexLife

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (MEDVi: 12-month plan applies to lowest rate; NexLife: cancel any time on monthly) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings